title: A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
abstract: Raltegravir (RAL), maraviroc (MVC), darunavir (DRV), and etravirine (ETV) are new antiretroviral agents with significant potential for drug interactions. This work describes a sensitive and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of plasma drug levels. Single-step extraction of RAL, MVC, DRV, ETV and RTV from plasma (100 microl) is performed by protein precipitation using 600 microl of acetonitrile, after the addition of 100 microl darunavir-d(9) (DRV-d(9)) at 1000 ng/ml in MeOH/H(2)O 50/50 as internal standard (I.S.). The mixture is vortexed, sonicated for 10 min, vortex-mixed again and centrifuged. An aliquot of supernatant (150 microl) is diluted 1:1 with a mixture of 20 mM ammonium acetate/MeOH 40/60 and 10 microl is injected onto a 2.1 x 50 mm Waters Atlantis-dC18 3 microm analytical column. Chromatographic separations are performed using a gradient program with 2 mM ammonium acetate containing 0.1% formic acid and acetonitrile with 0.1% formic acid. Analytes quantification is performed by electrospray ionisation-triple quadrupole mass spectrometry using the selected reaction monitoring detection in the positive mode. The method has been validated over the clinically relevant concentrations ranging from 12.5 to 5000 ng/ml, 2.5 to 1000 ng/ml, 25 to 10,000 ng/ml, 10 to 4000 ng/ml, and 5 to 2000 ng/ml for RAL, MRV, DRV, ETV and RTV, respectively. The extraction recovery for all antiretroviral drugs is always above 91%. The method is precise, with mean inter-day CV% within 5.1-9.8%, and accurate (range of inter-day deviation from nominal values -3.3 to +5.1%). In addition our method enables the simultaneous assessment of raltegravir-glucuronide. This is the first analytical method allowing the simultaneous assay of antiretroviral agents targeted to four different steps of HIV replication. The proposed method is suitable for the Therapeutic Drug Monitoring Service of these new regimen combinations administered as salvage therapy to patients having experienced treatment failure, and for whom exposure, tolerance and adherence assessments are critical.
authors.affiliation: Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Fayet
authors.forename: A
authors.initials: A
authors.lastname: Béguin
authors.forename: B
authors.initials: B
authors.lastname: Zanolari
authors.forename: S
authors.initials: S
authors.lastname: Cruchon
authors.forename: N
authors.initials: N
authors.lastname: Guignard
authors.forename: A
authors.initials: A
authors.lastname: Telenti
authors.forename: M
authors.initials: M
authors.lastname: Cavassini
authors.forename: H F
authors.initials: HF
authors.lastname: Günthard
authors.forename: T
authors.initials: T
authors.lastname: Buclin
authors.forename: J
authors.initials: J
authors.lastname: Biollaz
authors.forename: B
authors.initials: B
authors.lastname: Rochat
authors.forename: L A
authors.initials: LA
authors.lastname: Decosterd